Phaseline

Targets › CA9

CA9 (Carbonic anhydrase 9): drug programs, companies and trials

8 programs from 7 companies in 9 trials: 4 Phase 2, 4 Phase 1, 1 Phase 3; Oncology, Other; next expected readout Dec 2026.

Catalyzes the interconversion between carbon dioxide and water and the dissociated ions of carbonic acid (i.e. bicarbonate and hydrogen ions). (UniProt, Q16790)

Open in Phaseline: the race on CA9, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Telix Pharmaceuticals (Innovations)Girentuximab (TLX250)
Carbonic anhydrase IX other
CA9Phase 3Clear Cell Renal Cell Carcinoma–
IRCCS Ospedale San Raffaele[89Zr]Zr-DFO-Girentuximab
Carbonic anhydrase IX (CAIX) targeting radiopharmaceutical; girentuximab is an anti-CAIX m
CA9Phase 2VHL - Von Hippel-Lindau SyndromeDec 2026
Memorial Sloan Kettering Cancer Center177Lu-labeled-girentuximab
Radiolabeled anti-CA9 monoclonal antibody for targeted radionuclide therapy
CA9Phase 2Clear Cell Renal Cell CarcinomaMar 2027
Peking Union Medical College Hospital68Ga-NY104 PET/CT
CAIX-targeted PET tracer
CA9Phase 2Clear Cell Renal Cell CarcinomaSep 2028
Beijing BiotechEB-701/CA9-NK
Dual-target CD70/CAIX CAR-NK cells
CD70, CA9Phase 1Advanced or Metastatic Clear Cell Renal Cell CarcinomaApr 2027
M.D. Anderson Cancer Center177Lu girentuximab
Radiolabeled anti-CA9 monoclonal antibody
CA9Phase 1Advanced CancerOct 2027
PeptiDreamPD-32766D (Copper-64 [64Cu] labeled peptide)
64Cu-labeled peptide targeting carbonic anhydrase IX (CA9) for PET/CT imaging
CA9Phase 1Clear Cell Renal Cell CarcinomaMay 2029
PeptiDreamPD-32766T (Actinium-225 [225Ac] labeled peptide)
225Ac-labeled peptide targeting carbonic anhydrase IX (CA9) for targeted alpha particle th
CA9Phase 1Clear Cell Renal Cell CarcinomaMay 2029

Conditions

Clear Cell Renal Cell Carcinoma (6) Advanced Cancer (1) Advanced or Metastatic Clear Cell Renal Cell Carcinoma (1) VHL - Von Hippel-Lindau Syndrome (1)

Modalities

protein or peptide (3), mixed (3), antibody (2)

Companies

PeptiDream (2) Telix Pharmaceuticals (Innovations) (1) M.D. Anderson Cancer Center (1) Memorial Sloan Kettering Cancer Center (1) Beijing Biotech (1) IRCCS Ospedale San Raffaele (1) Peking Union Medical College Hospital (1)

Related targets

CD70 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.